S5-E13.6 – One Year Ago: When Global Fatty Live Day Was #NASHDay 2023
This conversation looks back to highlights of SurfingMASH’s coverage of GLI’s 2023 event, International NASHDAY.
May 5, 2024
This conversation looks back to highlights of SurfingMASH’s coverage of GLI’s 2023 event, International NASHDAY.
This closing conversation centers first around Roger’s use of the “blind people touching an elephant” metaphor to describe the complexity of MASH, and then creates a second goal, this time for providers to “rule out the liver.”
The group, including co-hosts Louise Campbell and Roger Green along with guests Jeff McIntyre and Mike Betel, dives deeper into the care challenges and barriers confronting MASH patient care today.
The conversation shifts to look first at challenges caused by explosion in the use of incretin agonists like GLP-1s to treat obesity and diabetes and second by the opportunities creating by on-site scanning.
Global Liver Institute Vice President of Liver Programs Jeff McIntyre describes the rational behind GLI’s 2024 theme, after which Mike Betel and Roger Green share reactions.
On April 23, SurfingMASH Co-founder Stephen Harrison passed away unexpectedly. This episode starts with panelists each sharing a memory of Stephen.
Patient advocates Jeff McIntyre (Global Liver Institute) and Mike Betel (Fatty Liver Alliance, Liver Action Network) join Louise Campbell and Roger Green to discuss GLI’s premier MASH patient event, now known as Global Fatty Livery Day.
This week’s vault episode looks back to last September, when Laurent Castera joined the Surfers to discuss different roles that NITs can play in MASH drug development and patient assessment.
This final conversation about MASH drug development includes continued discussion of combination therapies and a discussion on NITs’ vital role in speeding the process and making it more efficient.
Sven Francque and William Alazawi join the Surfers discuss the impact of concomitant metabolic therapies like incretin agonists on MASH Drug Development.